Finch Therapeutics Group, Inc. (FNCHQ): restructuring charge — Finch Therapeutics ends Phase 3 CP101 trial, cuts 95% of staff to focus on IP monetization

Finch Therapeutics Group, Inc.

Discontinued PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection; cites capital outlook, slow enrollment, unauthorized IP use.
Workforce reduced by 77 employees (~95% of employee base); most roles end Feb 2023, some continued into May 2023.
Expected restructuring costs of approximately $4.1 million from severance, outplacement and related expenses; charges recorded in H1 2023.
Company holds over 70 issued U.S. and foreign patents microbiome therapeutics and will seek to realize value from its IP estate.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Finch Therapeutics Group, Inc. announced a restructuring with charges of approximately $4.1 million (reduction of the Company’s workforce by 77 full-time employees, or approximately 95% of the Company’s current employee b).

Type: restructuring
Charge: approximately $4.1 million
Headcount: reduction of the Company’s workforce by 77 full-time employees, or approximately 95% of the Company’s current employee b

Exact text from the filing

On January 24, 2023, Finch Therapeutics Group, Inc. (the “Company”) announced decisions to discontinue its Phase 3 clinical trial of CP101 in recurrent C. difficile infection and to focus on realizing the value of its intellectual property estate and other assets. In connection with these decisions, on January 23, 2023, the Company’s board of directors approved certain expense reduction measures, including a reduction of the Company’s workforce by 77 full-time employees, or approximately 95% of the Company’s current employee base (the “Restructuring”). The Company initiated the Restructuring on January 24, 2023, with the majority of impacted positions ending in February 2023 and a small portion of positions maintained into May 2023. As a result of the Restructuring, the Company estimates that it will incur approximately $4.1 million in costs resulting from cash expenditures consisting of one-time severance payments, outplacement services and related expenses.

View on SEC.gov

Browse all restructurings & charges →

Finch Therapeutics Group, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-001046

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.